ASCO 2023 | Improving outcomes of BCMA-targeting ADCs in multiple myeloma
Hans Lee
• 4 Jun 2023
Hans Lee, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, explores strategies to improve outcomes associated with belantamab mafodotin and other BCMA-targeting antibody-drug conjugates (ADCs) in patients with multiple myeloma, where approximately 30% of patients exhibit durable responses. Dr Lee highlights the importance of patient stratification, as well as combination strategies involving gamma secretase inhibitors. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
